跳至主要内容
临床试验/NCT02067286
NCT02067286已完成不适用

Multi-Center Study of In Vitro Diagnostic Devices for the Detection of Influenza A, Influenza B, and RSV

IQuum, Inc.7 个研究点 分布在 1 个国家目标入组 1,642 人开始时间: 2014年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
IQuum, Inc.
入组人数
1,642
试验地点
7
主要终点
Evaluate the sensitivity and specificity of the Liat™ Influenza A/B & RSV Assay and the Liat™ Influenza A/B Assay as compared to an FDA-cleared nucleic acid amplification test

研究概览

简要总结

The objective of this study is to evaluate the clinical sensitivity and specificity of the Liat™ Influenza A/B & RSV Assay and the Liat™ Influenza A/B Assay when used on the Liat Analyzer to detect the presence or absence of Influenza A, Influenza B, and RSV in a nasopharyngeal swab specimen as compared to an FDA approved NAAT and culture.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients exhibiting 2 or more symptom groups characteristic of influenza and/or RSV at the time of visit or within the past 48 hours:
  • fever of at least 37.8 C (100F)
  • runny or stuffy nose
  • coughing, wheezing or difficulty breathing
  • sore throat, headache, extreme tiredness, or muscle aches
  • infants: decreased activity, irritability, poor feeding
  • Subject who are able to understand and consent to participation; for minors under the age of 18, this includes a parent or legal guardian

排除标准

  • Patients who are under-going anti-viral medication now or within the last 7 days.
  • Patients who received Nasal Spray Flu Vaccine within the last 6 weeks

结局指标

主要结局

Evaluate the sensitivity and specificity of the Liat™ Influenza A/B & RSV Assay and the Liat™ Influenza A/B Assay as compared to an FDA-cleared nucleic acid amplification test

时间窗: 1 day

次要结局

  • Evaluate the sensitivity and specificity of the Liat™ Influenza A/B & RSV Assay and the Liat™ Influenza A/B Assay as compared to culture(1 day)

研究者

发起方
IQuum, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验